Nasdaq:PCSA
Processa Pharmaceuticals, Inc.
A clinical-stage biopharma developer of novel therapies for rare pediatric diseases with no current revenue but significant cash flow from financing activities.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe in the transformative potential of the company's rare disease pipeline to generate massive first-in-class revenues upon approval. The ability to secure over $7M in financing capital demonstrates some investor confidence and provides a runway to advance key assets without immediate commercialization pressure.
Bear Case
The stock is highly speculative given zero revenue, a massive operating loss of -$11.9M, and a total asset base of only $3.2M which is insufficient to sustain long-term R&D without further dilution. The company faces an existential risk of running out of cash if share issuances cannot keep pace with its -$11.2M annual burn rate.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases, specifically targeting pediatric conditions like spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). The company serves the global rare disease market with proprietary asset portfolios aimed at addressing unmet medical needs where existing treatments are limited or non-existent. While currently operating without commercial revenue, the firm leverages its strategic partnerships to advance candidates through clinical development toward potential regulatory approval.
Analysis
Management Discussion
The company reported a net loss of $11.9M for the latest period, consistent with previous years of significant losses ranging from -$27.4M in 2022 to -$11.1M in 2023. Despite strong financing cash flow of $7.7M and common share issuances of $7.8M, the firm continues to burn through its limited liquid assets, with operating cash flow at -$11.2M and total assets only reaching $3.2M against liabilities of $1.5M.
Industry Overview
The rare disease biotechnology sector is characterized by high failure rates, significant regulatory hurdles, and a reliance on orphan drug exclusivity periods to recoup R&D investments. Companies in this space often operate without revenue for years while navigating complex clinical pathways to bring niche therapies to market with premium pricing potential.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $27.5M | $11.5M | $12.1M |
| Operating Income | $-27.5M | $-11.5M | $-12.1M |
| R&D | $11.5M | $5.8M | — |
| G&A | $8.8M | $5.7M | $4.8M |
| Stock-Based Comp | $8.8M | $1.1M | $629.5K |
| Depreciation | — | $222 | $782 |
| Amortization | $788.5K | — | — |
| Other OpEx | $7.3M | $0 | $7.3M |
| Non-Operating Income | $101.2K | $335.5K | $201.1K |
| Interest Income | $101.2K | $335.5K | $201.1K |
| Pre-Tax Income | $-27.4M | $-11.1M | $-11.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-27.4M | $-11.1M | $-11.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-27.4M | $-11.1M | $-11.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-27.4M | $-11.1M | $-11.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $8.4M | $5.6M | $1.9M |
| Cash & Equivalents | $6.5M | $4.7M | $1.2M |
| Prepaid Expenses | $1.9M | $926.3K | $682.3K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $233.1K | $154.1K | $1.4M |
| PP&E (Net) | — | $2.6K | $5.0K |
| Operating Leases | $227.6K | $146.1K | $70.7K |
| Other LT Assets | $5.5K | $5.5K | $1.3M |
| Total Assets | $8.6M | $5.8M | $3.2M |
| Current Liabilities | $998.6K | $730.6K | $1.5M |
| Accounts Payable | $327.5K | $311.6K | $880.9K |
| Current Leases | $78.9K | $83.6K | $66.9K |
| Other Current Liab | $189.1K | $189.0K | $6.1K |
| Long-Term Liabilities | $150.6K | $66.9K | $487 |
| LT Operating Leases | $150.6K | $66.9K | — |
| Other LT Liab | $0 | $0 | — |
| Total Liabilities | $1.1M | $797.5K | $1.5M |
| Shareholders' Equity | $7.5M | $5.0M | $1.7M |
| Retained Earnings | $-64.2M | $-75.4M | $-87.2M |
| Treasury Stock | $300.0K | $300.0K | $300.0K |
| Total L&E | $8.6M | $5.8M | $3.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-27.4M | $-11.1M | $-11.9M |
| Non-Cash Adjustments | $17.8M | $4.4M | $-1.3M |
| Working Capital Changes | $-18.0K | $-1.3M | $1.9M |
| Cash from Operations | $-9.6M | $-8.1M | $-11.2M |
| Capital Expenditures | — | $2.8K | $3.2K |
| Cash from Investing | $0 | $-2.8K | $-3.2K |
| Cash from Financing | $-388.8K | $6.3M | $7.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-10.0M | $-1.8M | $-3.5M |
| Beginning Cash | $16.5M | $6.5M | $4.7M |
| Ending Cash | $6.5M | $4.7M | $1.2M |
Frequently Asked Questions
How does Processa Pharmaceuticals, Inc. make money?
The company's financials reflect a single primary business segment focused on the research and development of orphan drug candidates, evidenced by zero cost of revenue and operating expenses dominated by general and administrative costs and share-based compensation typical of pre-commercial biotech firms.
What are the main risks for PCSA?
1. Complete lack of revenue and reliance on external capital injections, with a net change in cash of -$3.5M indicating rapid burn rate. 2. High probability of clinical trial failure leading to total loss of invested R&D capital. 3. Significant accumulated deficit of -$87.2M requiring continuous equity financing which may dilute existing shareholders. 4. Regulatory uncertainty and the stringent approval process for novel therapies in rare diseases.
What is PCSA's competitive advantage?
1. Specialized expertise in rare disease therapeutic areas with high patient unmet need. 2. Strategic partnerships that allow asset advancement without bearing the full R&D burden alone. 3. Capital-efficient development strategy supported by substantial cash inflows from share issuances to fund pipeline progression.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.